BRPI0410704A - uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete - Google Patents

uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete

Info

Publication number
BRPI0410704A
BRPI0410704A BRPI0410704-7A BRPI0410704A BRPI0410704A BR PI0410704 A BRPI0410704 A BR PI0410704A BR PI0410704 A BRPI0410704 A BR PI0410704A BR PI0410704 A BRPI0410704 A BR PI0410704A
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
diabetes
kinase
pdgf
treatment
Prior art date
Application number
BRPI0410704-7A
Other languages
English (en)
Inventor
Robert Per Hogerkvist
Nils Richard Welsh
Original Assignee
Robert Per Hogerkvist
Nils Richard Welsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312086A external-priority patent/GB0312086D0/en
Priority claimed from GB0402682A external-priority patent/GB0402682D0/en
Application filed by Robert Per Hogerkvist, Nils Richard Welsh filed Critical Robert Per Hogerkvist
Publication of BRPI0410704A publication Critical patent/BRPI0410704A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE INIBIDOR C-ABL-TIROSINA QUINASE, PDGF-R-TIROSINA QUINASE OU C-KIT-TIROSINA QUINASE NO TRATAMENTO DA DIABETE". A presente invenção refere-se ao uso de inibidor c-Abl- tirosina quinase, PDGF-R- tirosina quinase, ou c-kit-tirosina quinase, por exemplo 4(4-metilpiperazin-1-ilmetil)-N-¢4-metil-3-(4-piridin-3-il)-pirimidin-2ilamin o)fenil!-benzamida, ou um seu sal farmaceuticamente aceitável para a preparação de um medicamento para o tratamento da diabete, por exemplo, diabete do tipo I, diabete do tipo II.
BRPI0410704-7A 2003-05-27 2004-05-26 uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete BRPI0410704A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312086A GB0312086D0 (en) 2003-05-27 2003-05-27 Organic compounds
GB0402682A GB0402682D0 (en) 2004-02-06 2004-02-06 Organic compounds
PCT/EP2004/005679 WO2004105763A2 (en) 2003-05-27 2004-05-26 Use of tyrosine kinase inhibitor to treat diabetes

Publications (1)

Publication Number Publication Date
BRPI0410704A true BRPI0410704A (pt) 2006-06-13

Family

ID=33492240

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410704-7A BRPI0410704A (pt) 2003-05-27 2004-05-26 uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete

Country Status (20)

Country Link
US (1) US7875616B2 (pt)
EP (1) EP1631291B1 (pt)
JP (1) JP4776537B2 (pt)
KR (1) KR101102229B1 (pt)
AT (1) ATE439133T1 (pt)
BR (1) BRPI0410704A (pt)
CA (1) CA2526594C (pt)
DE (1) DE602004022540D1 (pt)
DK (1) DK1631291T3 (pt)
ES (1) ES2331800T3 (pt)
IL (1) IL171927A (pt)
IS (1) IS2712B (pt)
MA (1) MA27812A1 (pt)
MX (1) MXPA05012739A (pt)
NO (1) NO331715B1 (pt)
NZ (1) NZ543709A (pt)
PL (1) PL1631291T3 (pt)
PT (1) PT1631291E (pt)
RU (1) RU2365373C2 (pt)
WO (1) WO2004105763A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004013792D1 (de) * 2003-08-15 2008-06-26 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
JPWO2008001885A1 (ja) * 2006-06-30 2009-11-26 協和発酵キリン株式会社 Ａｂｌキナーゼ阻害剤
US20140221389A1 (en) * 2011-09-15 2014-08-07 Novartis Ag Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (pt) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CZ283339B6 (cs) * 1993-09-15 1998-03-18 Sankyo Company Limited Použití thiazolidinových derivátů pro výrobu léčivého přípravku pro léčení zhoršené tolerance glukosy pro zabránění nebo zpoždění nástupu diabetes mellitus nezávislé na inzulinu
EP0773313B1 (de) * 1995-10-11 2000-08-09 ARTEVA TECHNOLOGIES S.à.r.l. Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
ATE289586T1 (de) * 1999-03-01 2005-03-15 Pfizer Prod Inc Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
KR20020072312A (ko) * 2000-02-15 2002-09-14 테바 파마슈티컬 인더스트리즈 리미티드 레플루노미드를 합성하는 방법
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
TWI270545B (en) * 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2002055517A2 (en) 2000-12-20 2002-07-18 Jingrong Cui 4-(hetero)aryl substituted indolinones
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AUPS243002A0 (en) 2002-05-20 2002-06-13 Baker Medical Research Institute Therapeutic target and uses thereof
DE10235227A1 (de) * 2002-08-01 2004-02-19 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
AU2003295604A1 (en) * 2002-11-13 2004-06-03 Genpath Pharmaceuticals, Incorporated Gpc15: methods and compositions for treating cancer
DE10255360A1 (de) * 2002-11-27 2004-06-17 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes

Also Published As

Publication number Publication date
NZ543709A (en) 2009-04-30
JP4776537B2 (ja) 2011-09-21
EP1631291B1 (en) 2009-08-12
PT1631291E (pt) 2009-10-28
RU2365373C2 (ru) 2009-08-27
AU2004243491A1 (en) 2004-12-09
DK1631291T3 (da) 2009-11-02
CA2526594C (en) 2011-11-08
IL171927A0 (en) 2006-04-10
WO2004105763A2 (en) 2004-12-09
PL1631291T3 (pl) 2010-04-30
US7875616B2 (en) 2011-01-25
JP2006528225A (ja) 2006-12-14
DE602004022540D1 (de) 2009-09-24
ATE439133T1 (de) 2009-08-15
IS2712B (is) 2011-01-15
IS8139A (is) 2005-11-22
EP1631291A2 (en) 2006-03-08
ES2331800T3 (es) 2010-01-15
RU2005140516A (ru) 2007-07-10
HK1087638A1 (en) 2006-10-20
KR20060021865A (ko) 2006-03-08
US20070072932A1 (en) 2007-03-29
KR101102229B1 (ko) 2012-01-05
MA27812A1 (fr) 2006-03-01
CA2526594A1 (en) 2004-12-09
IL171927A (en) 2011-10-31
NO331715B1 (no) 2012-03-05
MXPA05012739A (es) 2006-05-17
NO20056188L (no) 2005-12-23
WO2004105763A3 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
NO20052512L (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
DK1682553T3 (da) Thienopyrazoler
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
ECSP077845A (es) Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
SE0200198D0 (sv) New use
BRPI0410704A (pt) uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete
ATE399555T1 (de) Behandlung der rheumatoiden arthritis mit imitanib
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
WO2006012958A3 (en) Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
TNSN05304A1 (en) Use of tyrosine kinase inhibitor to treat diabetes
NO20072501L (no) Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMS
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
CY1105785T1 (el) Μεθοδοι παρασκευης της 2-(7-χλωρο-1,8-ναφθυριδιν-2-υλ)-3-(5-μεθυλ-2-οξο-εξυλ)-1-ισοϊνδολινονης

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI